0000000000628239
AUTHOR
René G. Yoa
Effects of repeated treatments with an extract ofGinkgo biloba (EGb 761) and bilobalide on liver and muscle glycogen contents in the non-insulin-dependent diabetic rat
The effects of repeated (15-day) oral treatments with an extract of Ginkgo biloba (EGb 761; 50 mg/kg/day) or with its terpenoid constituent, bilobalide (2 mg/kg/day), were assessed in normal rats and in rats that had been previously injected with streptozotocin (50 mg/kg, i.p. in saline solution), a dose which provided a model of non-insulin-dependent diabetes mellitus (NIDDM). In this model of diabetes, blood glucose is significantly increased while the circulating insulin level remains unchanged. Glucose penetrates cells because of decreased glycogen turnover, a metabolic abnormality that can be revealed by using an oral glucose tolerance test (OGTT). In control rats, hyperglycemia was ac…
Effect of the extract of Ginkgo biloba (EGb 761) on the circulating and cellular profiles of polyunsaturated fatty acids: correlation with the anti-oxidant properties of the extract
Abstract Ginkgo biloba extract (EGb 761) has beneficial effects on cognitive functions in aging patients, and on various pathologies, including cardiovascular diseases. Although the extract is known to have antioxidant properties and improve membrane fluidity, the cellular mechanisms underlying these effects have not been determined. Here, we examined the in vivo effects of EGb 761 on circulating and cellular lipids. EGb 761 treatment induced significant increases in the levels of circulating polyunsaturated fatty acids (PUFAs), and a decrease in the saturation index SI (saturated/polyunsaturated species). Plasma triglycerides and cholesterol were not affected, while phospholipids were slig…